Cargando…

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease. Repetitive injury and reprogramming of the lung epithelium are thought to be critical drivers of disease progression, contributing to fibroblast activation, extracellular matrix remodeling, and subsequently loss of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehmann, Mareike, Buhl, Lara, Alsafadi, Hani N., Klee, Stephan, Hermann, Sarah, Mutze, Kathrin, Ota, Chiharu, Lindner, Michael, Behr, Jürgen, Hilgendorff, Anne, Wagner, Darcy E., Königshoff, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138909/ https://www.ncbi.nlm.nih.gov/pubmed/30219058 http://dx.doi.org/10.1186/s12931-018-0876-y

Ejemplares similares

Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis ex vivo
por: Lehmann, Mareike, et al.
Publicado: (2017)

Linking bronchopulmonary dysplasia to adult chronic lung diseases: role of WNT signaling
por: Ota, Chiharu, et al.
Publicado: (2016)

Dynamic expression of HOPX in alveolar epithelial cells reflects injury and repair during the progression of pulmonary fibrosis
por: Ota, Chiharu, et al.
Publicado: (2018)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
por: Roach, KM, et al.
Publicado: (2021)

S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis
por: Zhang, Wei, et al.
Publicado: (2018)

No involvement of alveolar macrophages in the initiation of carbon nanoparticle induced acute lung inflammation in mice
por: Chen, Shanze, et al.
Publicado: (2016)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review
por: Amati, Francesco, et al.
Publicado: (2023)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
por: Belhassen, Manon, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
por: Rinciog, C., et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
por: Kaushal, Mohit, et al.
Publicado: (2022)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
por: Takehara, Kazutaka, et al.
Publicado: (2022)

Enolase 1 (ENO1) and protein disulfide-isomerase associated 3 (PDIA3) regulate Wnt/β-catenin-driven trans-differentiation of murine alveolar epithelial cells
por: Mutze, Kathrin, et al.
Publicado: (2015)

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
por: Marijic, Pavo, et al.
Publicado: (2021)

Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine
por: Myllärniemi, Marjukka, et al.
Publicado: (2015)

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
por: Hughes, Gareth, et al.
Publicado: (2016)

Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study
por: Moor, C. C., et al.
Publicado: (2020)

Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
por: Serra López-Matencio, José M., et al.
Publicado: (2021)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts
por: Klee, S., et al.
Publicado: (2016)

Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone
por: Ipatova, Anastasia Y, et al.
Publicado: (2019)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study
por: Choudhary, Rajkamal, et al.
Publicado: (2022)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis
por: Strunz, Maximilian, et al.
Publicado: (2020)

microRNA Expression Profile of Purified Alveolar Epithelial Type II Cells
por: Dehmel, Stefan, et al.
Publicado: (2022)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
por: Fois, Alessandro G., et al.
Publicado: (2020)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
por: Chu, Kuo-An, et al.
Publicado: (2020)

Modeling fibrotic alveolar transitional cells with pluripotent stem cell-derived alveolar organoids
por: Ptasinski, Victoria, et al.
Publicado: (2023)

Talaromycosis in a Patient on Nintedanib for Interstitial Lung Disease
por: Madgula, Anantha Sriharsha, et al.
Publicado: (2020)

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases
por: Lamb, Yvette N.
Publicado: (2021)

Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib
por: Bourne, Michael H., et al.
Publicado: (2021)

Nintedanib in children and adolescents with fibrosing interstitial lung diseases
por: Deterding, Robin, et al.
Publicado: (2023)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2019)

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
por: Cameli, Paolo, et al.
Publicado: (2020)

Effect of pirfenidone on wound healing in lung transplant patients
por: Mortensen, Amber, et al.
Publicado: (2018)

Safety of nintedanib before lung transplant: an Italian case series
por: Balestro, Elisabetta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2cpgpsbsiq7dg8sseon13f03pd